To treat ovarian cancer, the deadliest of all cancers affecting the female reproductive system, few effective treatments have been approved.
Now, new research from The Wistar Institute demonstrates how a drug already in clinical trials could be used to boost anti-tumor immunity and cause T-cells to target the cancer directly while minimizing side effects. The results were published in the journal Cell Reports.
‘BET inhibitors impact the PD-L1 pathway, a major therapeutic target in a variety of tumors.’
AdvertisementThere has been considerable interest in the programmed cell death-1 (PD-1) protein and its ligand (PD-L1) because the interaction between the two inhibits important T-cell activity aimed at stopping tumor growth. PD-L1 is expressed on the surface of both cancer cells and immune cells across many different cancer types. Antibody-based drugs that specifically halt this interaction have shown promising results, though patients have experienced immune-related side effects as a result.
"We wanted to explore anti-PD-L1 therapies specifically for ovarian cancer, but we also wanted to determine if other drugs that did not cause these negative anti-PD-L1 antibody-related side effects could be used to target this cancer-promoting pathway," said Rugang Zhang, Ph.D., professor and co-program leader in the Gene Expression and Regulation program at The Wistar Institute and lead author of the study.
Zhang and his team decided to screen for small molecule inhibitors that could be used as a treatment option. Small molecule inhibitors are a preferable form of cancer treatment because they block cancer progression by targeting cells that have proteins or mutations associated with cancer while sparing normal, healthy cells.
The researchers found that a class of drugs known as bromodomain and extraterminal domain (BET) inhibitors were particularly effective at suppressing PD-L1 activity when they studied the drug in epithelial ovarian cancer cell lines. Multiple BET inhibitors are in various stages of clinical trials for different types of cancer. They are able to suppress inflammatory responses, and they may be able to do so without affecting the anti-tumor immune response. In this study, they used an experimental BET inhibitor called JQ1.
Even though BET inhibitors do not specifically target PD-L1, the researchers were able to determine why this class of drugs is so effective. They showed that bromodomain-containing protein 4 (BRD4), one of the members of the BET family that is inhibited by these drugs, is a critical regulator of PD-L1 expression. The BRD4 gene is often amplified in ovarian cancer and may serve as a valuable biomarker to determine which ovarian cancer patients could benefit the most from receiving treatment with BET inhibitors.
"Targeting PD-L1 appears to be an effective strategy for combating a variety of human cancers," said Hengrui Zhu, Ph.D., a postdoctoral fellow in the Zhang lab and first author of the study. "With BET inhibitors, we believe we have found a powerful new addition to available therapeutic strategies for ovarian cancer."
This work was supported by the National Institutes of Health/National Cancer Institute R01 grants CA160331, CA163377, CA202919 and K99CA194318, U.S. Department of Defense grants OC140632P1 and OC150446, an Ovarian Cancer Research Fund (OCRF) program project and The Jayne Koskinas & Ted Giovanis Breast Cancer Research Consortium at Wistar. Zhu is an OCRF Ann Schreiber Mentored Investigator. Support for shared resources used in this study was provided by Cancer Center Support Grant (CCSG) CA010815 to The Wistar Institute. The Structure Genomics Consortium provided the panel of small molecule inhibitors that target epigenetic regulators used in this study.
Co-authors of this study from The Wistar Institute include Fee Bengsch, Nikolaos Svoronos, Melanie Rutkowski, Benjamin Bitler, Michael Allegrezza, Yuhki Yokoyama, Andrew Kossenkov, and José Conejo-Garcia. James Bradner from Dana-Faber Cancer Institute was also a co-author of this study.